Organization | Soochow University

Soochow University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Suzhou China (1900)

Organization Overview

First Clinical Trial

2008

NCT00813137

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

a staff of The Second Affiliated Hospital of Soochow University | Changzhou Cancer Hospital of Soochow University | Children's Hospital Of Soochow University | Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou | First Affiliated Hospital of Soochow University | First Affiliated Hospital of Suzhou University | First Affiliated Hospital, Soochow University | First Affiliated Hospital,Soochow University | First Affiliated Hospital, Soochow University Suzhou, Jiangsu, China, 215000 | First affiliated Hospital,Suzhou University,Suzhou,China | first affiliated of Soochow university | Hematology，The First Affiliaated Hospital Of Soochow University | Medical Ethics Committee of the First Affiliated Hospital of soochow University | Second Affiliated Hospital of Soochow University | Second Affiliated Hospital of Suzhou University | Second Afflilated Hospital of Soochow University | Soochow University | Suzhou Kowloon Hospital | Suzhou Municipal Hospital | Suzhou University | Suzhou University Affiliated Children's Hospital | Suzhou University Affiliated First Hospital | Suzhou University Affiliated Second Hospital | The Affiliated Changzhou Tumor Hospital of Suzhou University | the first affiliated hospital of Soochow Uninersity | The First Affiliated Hospital of Soochow University | The First Affiliated Hospital of Suzhou University | The First Affliated Hospital of Soochow University | The Second Affiliated Hospital of Soochow University

Active Ingredients

Drugs in Phase 4 Trials (24)

agomelatine (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

bortezomib (velcade) (5 trials)

decitabine (dacogen) (11 trials)

dexamethasone (4 trials)

dexmedetomidine (precedex) (1 trial)

doxorubicin (Doxil) (2 trials)

etoposide (vepesid) (1 trial)

exenatide (byetta) (2 trials)

glimepiride (amaryl) (1 trial)

idebenone (2 trials)

methylcantharidimide (1 trial)

oseltamivir (tamiflu) (1 trial)

propofol (diprivan) (1 trial)

reduning (1 trial)

rosuvastatin (crestor) (1 trial)

ruxolitinib (jakafi) (3 trials)

sargramostim (leukine) (6 trials)

saxagliptin (onglyza) (1 trial)

selegiline (zelapar) (1 trial)

sitagliptin (januvia) (3 trials)

somatropin (protropin) (3 trials)

urea (3 trials)

vancomycin (Vancocin) (1 trial)

Drugs in Phase 3 Trials (49)

acetylcysteine (mucomyst) (4 trials)

aclarubicin (3 trials)

aminophylline (aminophyllin) (1 trial)

anlotinib (2 trials)

autologous mesenchymal stem cell-derived neural progenitors (1 trial)

autologous umbilical cord blood (1 trial)

avatrombopag (1 trial)

azacitidine (vidaza) (11 trials)

busulfan (myleran) (1 trial)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (2 trials)

cetuximab (erbitux) (1 trial)

ciltacabtagene autoleucel (Carvykti) (5 trials)

cisplatin (platinol) (6 trials)

cladribine (leustatin) (4 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (7 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (12 trials)

decitabine plus modified bucy (1 trial)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (1 trial)

epoetin (Epogen) (1 trial)

filgrastim (neupogen) (6 trials)

fludarabine (fludara) (4 trials)

fluorouracil (efudex) (4 trials)

gefitinib (iressa) (3 trials)

gelatin (1 trial)

gemcitabine (gemzar) (1 trial)

hetrombopag olamine (2 trials)

icaritin (1 trial)

idarubicin (idamycin) (4 trials)

irinotecan (Camptosar) (2 trials)

lenalidomide (revlimid) (3 trials)

lipiodol (1 trial)

mycophenolate (myfortic) (1 trial)

nedaplatin (1 trial)

neuregulin (1 trial)

omacetaxine (synribo) (3 trials)

platelets (1 trial)

Raltitrexed (1 trial)

semustine (1 trial)

sodium chloride (2 trials)

sorafenib (nexavar) (1 trial)

thrombopoietin (5 trials)

tretinoin (Retin-A) (2 trials)

venetoclax (venclexta) (9 trials)

vinorelbine (navelbine) (3 trials)

visilizumab (1 trial)

Drugs in Phase 2 Trials (53)

abatacept (orencia) (1 trial)

abiraterone (zytiga) (2 trials)

ak117 (1 trial)

aldesleukin (proleukin) (3 trials)

anti-flt3 car-t (1 trial)

apatinib (2 trials)

autologous cd19/cd22 chimeric antigen receptor t-cells (2 trials)

bacille calmette-guerin (1 trial)

bcma-pd1-cart cell (1 trial)

bevacizumab (avastin) (2 trials)

calcium (1 trial)

car-t (1 trial)

car-t targeted cd19/cd20/cd22/cd30 (1 trial)

cd19 car-t cells (9 trials)

cd38 car-t cells (1 trial)

cd7 car-t cell (3 trials)

chidamide (5 trials)

cll-1 cart-t cell (1 trial)

deferasirox (exjade) (1 trial)

eltrombopag (promacta) (1 trial)

endostatin (endostar) (2 trials)

ensartinib (1 trial)

erlotinib (tarceva) (1 trial)

flumatinib (1 trial)

gimeracil (2 trials)

hlx10 (1 trial)

house dust mite allergen (1 trial)

hqp1351 (2 trials)

humanized cd19 car-t cells with crs suppression technology (1 trial)

interferon alfa-1b (1 trial)

kd025 (1 trial)

kn046 (1 trial)

leucovorin (1 trial)

lm-305 (1 trial)

neu2000kwl (1 trial)

nimotuzumab (1 trial)

niraparib (zejula) (1 trial)

orelabrutinib (1 trial)

oteracil (2 trials)

oxaliplatin (eloxatin) (2 trials)

pamiparib (1 trial)

prednisone (meticorten) (4 trials)

rituximab (rituxan) (4 trials)

selinexor (Xpovio) (1 trial)

sintilimab (4 trials)

stromal vascular fraction (1 trial)

tegafur (2 trials)

tislelizumab (1 trial)

trastuzumab (herceptin) (1 trial)

vincristine (oncovin) (2 trials)

vitamin d3 (1 trial)

zanubrutinib (Brukinsa) (2 trials)

Drugs in Phase 1 Trials (29)

[68ga]ga-nota-sna002 (1 trial)

68ga-nodaga-sna006 (1 trial)

afuresertib (1 trial)

alflutinib (1 trial)

apg2575 (1 trial)

autologous fecal microbiota (1 trial)

autologous mesenchymal stem cells (1 trial)

autologous tumor infiltrating lymphocytes (1 trial)

bone marrow derived mononuclear cells (1 trial)

bronchial basal cells (1 trial)

chlorogenic acid (1 trial)

collagen (1 trial)

ct0591cp (1 trial)

dapagliflozin (farxiga) (1 trial)

gamma-delta t cells (1 trial)

hsk3486 (1 trial)

hsk7653 (1 trial)

ibi188 (1 trial)

IBI-346 (1 trial)

jaktinib (2 trials)

levothyroxine (Synthroid) (1 trial)

metformin (glucophage) (1 trial)

pemetrexed (alimta) (1 trial)

pyroglutamic acid (1 trial)

shr-1314 (1 trial)

sscart-19 cells (1 trial)

vicagrel (1 trial)

voriconazole (vfend) (1 trial)

Drugs in Other Trials (11)

azathioprine (imuran) (1 trial)

cs-2164 (1 trial)

ct0590 car t cells (1 trial)

daratumumab (darzalex) (1 trial)

epinephrine (levophed) (1 trial)

fenofibrate (fenoglide) (1 trial)

human fecal microbiota (Reybota) (1 trial)

icotinib (1 trial)

lactobacillus reuteri (1 trial)

leflunomide (arava) (1 trial)

pemigatinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Habitual (Phase 1)

Abortion, Spontaneous (Phase 1)

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Cerebral Infarction (Phase 2)

Chronobiology Disorders (Phase 4)

Colorectal Neoplasms (Phase 3)

Delirium (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 4)

Dwarfism, Pituitary (Phase 4)

Eczema (Phase 2)

Endocarditis (Phase 4)

Endocrine System Diseases (Phase 4)

Esophageal Squamous Cell Carcinoma (Phase 2)

Fetal Death (Phase 1)

Glioma (Phase 2)

Headache (Phase 3)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Hematologic Diseases (Phase 3)

Hepatoblastoma (Phase 4)

Hip Fractures (Phase 4)

Hypothyroidism (Phase 1)

Infarction (Phase 4)

Infarction, Anterior Cerebral Artery (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 4)

Leukemia (Phase 4)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Leukemia, Promyelocytic, Acute (Phase 4)

Leukemia, T-Cell (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Mental Disorders (Phase 2)

Multiple Myeloma (Phase 4)

Myelodysplastic Syndromes (Phase 4)

Nasopharyngeal Carcinoma (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 4)

Neoplasms, Squamous Cell (Phase 3)

Neuroblastoma (Phase 4)

Osteoporosis (Phase 2)

Osteoporosis, Postmenopausal (Phase 2)

Ovarian Neoplasms (Phase 2)

Parasomnias (Phase 4)

Parkinson Disease (Phase 4)

Post-Dural Puncture Headache (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 4)

REM Sleep Behavior Disorder (Phase 2)

Respiration Disorders (Phase 1)

Respiratory Tract Diseases (Phase 1)

Retinoblastoma (Phase 4)

Skin Abnormalities (Phase 2)

Sleep Wake Disorders (Phase 4)

Small Cell Lung Carcinoma (Phase 3)

Spinal Cord Injuries (Phase 1)

Spondylarthritis (Phase 1)

Stomach Neoplasms (Phase 2)

Stroke (Phase 2)

Syndrome (Phase 4)

Thrombocytopenia (Phase 3)

Thrombosis (Phase 3)

Thrombotic Microangiopathies (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 173
# of Trial APIs: 166